
NASDAQHealthcareBiotechnology
最新資料
US$13.66
−US$1.20 · -8.08%
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
前收盤價
US$13.66
−US$1.20 · -8.08%
盤中時間採用ET。市場資料可能有所延遲。
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
日內區間
目前US$13.66
52週區間
目前US$13.66
盤中時間採用ET。市場資料可能有所延遲。
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
日內區間
目前US$13.66
52週區間
目前US$13.66
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 100萬 USD | 760萬 USD |
| 銷貨成本 | — | — | — | 10萬 USD | 20萬 USD |
| 毛利 | — | — | — | 90萬 USD | 740萬 USD |
| 研究與開發 | 1602.2萬 USD | 1909.6萬 USD | 2400.7萬 USD | 3026.8萬 USD | 2137.4萬 USD |
| 銷售、一般及管理費用 | 1225.2萬 USD | 1241.7萬 USD | 1386.2萬 USD | 1258.2萬 USD | 1132萬 USD |
| 營業費用 | 2827.4萬 USD | 3151.3萬 USD | 3786.9萬 USD | 4285萬 USD | 3269.4萬 USD |
| 利息收入 | 141.1萬 USD | 63.2萬 USD | 52.5萬 USD | 31.7萬 USD | 6000 USD |
| 折舊和攤銷 | — | 3151.3萬 USD | 3786.9萬 USD | 45.7萬 USD | 127.3萬 USD |
| 營業利益 | −2827.4萬 USD | −3151.3萬 USD | −3786.9萬 USD | −4195萬 USD | −2529.4萬 USD |
| 淨利 | −2686.3萬 USD | −3088.1萬 USD | −3734萬 USD | −4130.1萬 USD | −2069.9萬 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$35.00
上漲空間 156.22%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年11月8日 | 1:50 | — | — |
股票分割 | 2018年1月2日 | 1:30 | — | — |
股票分割 | 2016年11月14日 | 1:20 | — | — |
已生效 2019年11月8日
1:50
已生效 2018年1月2日
1:30
已生效 2016年11月14日
1:20
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI8630.15萬0.90%96.36億 USD0.35%US$140.18-2.73%
iShares Russell 2000 ETFIWM7389.39萬0.10%715.37億 USD0.19%US$256.61-2.88%
iShares Russell 2000 Growth ETFIWO2831.18萬0.21%127.32億 USD0.24%US$320.43-3.57%
Vanguard Extended Market ETFVXF2215.68萬0.02%302億 USD0.05%US$211.44-3.21%
Schwab U.S. Small-Cap ETFSCHA1562.09萬0.08%204.47億 USD0.03%US$30.51-2.83%
Vanguard Russell 2000 ETFVTWO1144.64萬0.06%168億 USD0.06%US$103.76-2.76%
iShares Micro-Cap ETFIWC830.35萬0.77%10.88億 USD0.60%US$157.87-3.19%
Vanguard Health Care ETFVHT583.94萬0.02%208億 USD0.09%US$326.69-0.40%
State Street SPDR S&P Biotech ETFXBI
iShares Russell 2000 ETFIWM
iShares Russell 2000 Growth ETFIWO
Vanguard Extended Market ETFVXF
Schwab U.S. Small-Cap ETFSCHA
Vanguard Russell 2000 ETFVTWO
iShares Micro-Cap ETFIWC
Vanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。